Whether you are licensing your own intellectual property or paying for the right to use someone else’s technology, software, trademark, know-how or other IP, the royalty structure is one of the key factors determining the financial value of the deal.
But the royalty percentage alone rarely tells the full story.
In practice, the economics of a licensing agreement are shaped by a combination of payment mechanisms, definitions, thresholds, duration rules and adjustment mechanisms. A royalty rate that looks attractive on paper may become much less favourable once the definition of net sales, royalty reductions, third-party licence costs or the duration of the royalty obligation are taken into account.
This is why the economics of a licensing agreement should be assessed as a whole rather than by focusing only on the headline royalty rate.
What Are Royalties?
Royalties are payments made by a licensee (the party using intellectual property) to a licensor (the owner or authorised licensor of that intellectual property) in exchange for the right to use it. A licensing arrangement generally does not involve a transfer of ownership. Instead, the licensor authorises another party to use the relevant IP under agreed conditions while retaining ownership of the underlying rights.
Businesses commonly use royalty-based licensing agreements to commercialise valuable intellectual property, including:
- trade marks and brands;
- software and technology;
- patents;
- biotechnological inventions;
- copyrighted works;
- know-how;
- manufacturing technologies;
- trade secrets; and
- industrial designs.
For licensors, royalties can create a scalable revenue stream while allowing them to retain ownership of the underlying IP. For licensees, royalty payments form part of the overall cost of accessing and commercialising technology and therefore need to be assessed against expected margins, development costs and commercial potential.
Importantly, sophisticated licensing transactions rarely rely on royalties alone. Particularly in technology, pharmaceutical and biotech transactions, the financial structure may include an upfront payment, development or regulatory milestones, commercial milestones and running royalties on sales.
Common Royalty Models
There is no single royalty model that works for every transaction. The appropriate structure depends on the industry, maturity of the technology, allocation of development risk, expected sales volumes and bargaining position of the parties.
Percentage of Sales
The licensee pays an agreed percentage of sales generated from products or services using the licensed intellectual property.
In many agreements, royalties are calculated on Net Sales rather than gross revenue. The definition of Net Sales therefore becomes just as important as the headline royalty rate, as it determines which discounts, rebates, taxes, returns or other deductions may reduce the royalty base.
Royalty rates do not necessarily remain constant. The parties may agree on tiered royalties, where different rates apply to different levels of annual sales.
Importantly, tiered royalties may operate progressively, with each rate applying only to the portion of sales falling within the relevant band, rather than the higher rate automatically applying to all sales once a threshold is crossed.
This means that the commercial effect of a tiered structure depends not only on the percentages themselves, but also on how the thresholds operate.
Fixed Licence Fee
Instead of variable payments, the parties may agree on a fixed monthly, quarterly or annual licence fee. This model provides predictable budgeting and may work particularly well where sales are relatively stable or difficult to measure. However, the parties should consider whether the fixed fee adequately reflects changes in the scale of the licensee’s business over time.
Per-Unit Royalties
In manufacturing and product-based businesses, royalties may be calculated as a fixed amount for every unit sold. This can simplify royalty calculations, particularly where products are standardised, but the agreement should address issues such as bundled products, promotional units, free samples and changes in pricing.
Minimum Guaranteed Royalties
A licensor may require a minimum annual royalty regardless of actual sales. Apart from providing a minimum level of income, this mechanism can also serve an important commercial purpose: preventing a licensee from obtaining valuable exclusive rights and then failing to actively exploit them. Minimum royalties are therefore often closely linked to exclusivity, minimum sales commitments or other commercialisation obligations.
Hybrid Models
In significant technology licensing transactions, hybrid structures are often more relevant than any single payment mechanism.
A deal may combine:
- an upfront licence fee;
- research or development funding;
- development, regulatory or commercial milestone payments;
- running royalties on Net Sales;
- minimum annual royalties; and
- payments connected with sublicensing.
Each element reflects a different part of the risk allocation between the parties.
An upfront payment may compensate the licensor for granting access to the technology at the beginning of the relationship. Milestone payments allocate value to later stages of development, regulatory progress or commercial success. Running royalties allow the licensor to participate in the long-term commercial performance of the licensed product.
This is why the economic value of a licence should be assessed as a package, rather than by looking only at the royalty percentage.
The Headline Royalty Rate Is Only the Starting Point
Two agreements providing for the same 5% royalty may produce very different economic outcomes. Several provisions can materially affect what is ultimately paid.
Net Sales
The definition of Net Sales determines the royalty base. The agreement should clearly identify permitted deductions and address, where relevant, matters such as discounts, rebates, returns, taxes, related-party transactions, bundled products and non-cash consideration.
A seemingly small difference in the Net Sales definition can have a significant financial impact over the life of the agreement.
Royalty Tiers and Thresholds
Royalty rates may increase or decrease depending on the level of annual sales. Businesses should therefore model the economics of the licence at several realistic sales scenarios rather than considering only the initial rate.
The key questions are not only what the rates are, but also how the thresholds operate and whether they apply progressively or in another agreed manner.
Royalty Term
The agreement should specify precisely how long royalties remain payable. In patent-heavy transactions, the royalty term may be linked to the existence of enforceable patent protection, regulatory exclusivity, a minimum number of years from first commercial sale, or a combination of these mechanisms.
The royalty term may also operate on a product-by-product and country-by-country basis. That distinction matters because royalty obligations may therefore end at different times in different markets.
Royalty Reductions and Adjustments
The royalty agreed at signing does not necessarily remain unchanged throughout the entire life of the licence. Depending on the transaction, the agreement may provide for adjustments if the commercial or IP landscape changes: for example, where third-party technology must be licensed, relevant patent protection is no longer available, or competing generic or equivalent products enter the market.
Where third-party rights are required to develop, manufacture or commercialise the licensed product, the licensee may be permitted to offset part of those additional royalty costs against amounts payable to the licensor. Such reductions are often subject to an agreed minimum royalty floor.
The important point is not simply whether a reduction exists, but which event triggers it, how it is calculated and how far the royalty can ultimately fall.
These provisions can materially affect the real economic value of the licence and should not be treated as secondary drafting details.
Milestones Matter Too
Particularly in life-sciences and technology transactions, much of the potential deal value may sit outside the running royalty itself.
Milestone payments are typically linked to predefined development, regulatory or commercial achievements. They allow the parties to align payments with the progress of the licensed technology and its commercial success, while distributing financial risk across different stages of the project.
When reviewing milestone provisions, the amount of the payment is only one issue. The commercial value of milestone payments depends not only on their amounts, but also on how they are structured. Clear and carefully negotiated milestone provisions are essential to ensuring that the agreed payment structure reflects the parties’ commercial expectations and remains workable as the licensed technology develops
Beyond the Royalty Rate: Other Financial Considerations
The economics of a licensing agreement are also influenced by how royalties are reported, verified and paid. Reporting and audit mechanisms, as well as cross-border tax and currency considerations, can all affect the financial value of the arrangement. Although these aspects often receive less attention than the headline royalty rate, they are important to ensuring that the commercial terms translate into the expected financial outcomes.
Before You Sign: Key Questions to Consider
Before entering into a licensing agreement, it is worth looking beyond the headline royalty rate and considering how the financial structure will work in practice:
1. Royalty calculation: Is the basis for calculating royalties clearly defined and commercially reasonable?
2. Payment structure: Does the combination of upfront payments, milestones and ongoing royalties reflect the expected value and development stage of the technology?
3. Commercial performance: How does the payment structure respond to different commercial outcomes?
4. Sublicensing: Are the financial implications of sublicensing appropriately addressed?
5. Duration: Is the royalty payment period aligned with the commercial and IP protection strategy?
6. Changing circumstances: Can the financial arrangements accommodate changes in the technology, market or competitive environment?
7. Financial transparency: Are there appropriate mechanisms to ensure transparency and accountability in royalty payments?
8. International transactions: Have relevant tax, currency and cross-border payment considerations been taken into account?
Not every transaction requires all of these mechanisms.
The key question is not simply whether the royalty rate is attractive, but whether the agreement as a whole supports the commercial objectives of the transaction.